Literature DB >> 20728391

[Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].

M Bolla1, P Fourneret, V Beneyton, A Tessier, F Jover, C Verry.   

Abstract

The combination of radiotherapy and androgen suppression with luteinizing hormone releasing hormone agonist is mainly devoted to locally advanced prostate cancer and intermediate or poor risk localized prostate cancer. They are based on phase III randomized trials which have shown that for locally advanced prostate cancer, a four-month complete androgen blockade initiated two months prior radiotherapy and stopped at the completion of radiotherapy increased overall survival in patients with Gleason scores 2-6, meanwhile, an adjuvant long-term androgen suppression (2.5 to three years) improved significantly the overall survival. Complete androgen blockade with a four to six months duration, combined with external irradiation, enhanced the overall survival in patients with intermediate or poor risk localized prostate cancer.
Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20728391     DOI: 10.1016/j.canrad.2010.07.226

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  3 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

Review 2.  Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: Summary of level 1 evidence and current gaps in knowledge.

Authors:  Jérémy Baude; Matthieu Caubet; Blanche Defer; Charles Régis Teyssier; Edouard Lagneau; Gilles Créhange; Nicolas Lescut
Journal:  Clin Transl Radiat Oncol       Date:  2022-07-21

3.  Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.

Authors:  T J Johnson; N Höti; C Liu; W H Chowdhury; Y Li; Y Zhang; S E Lupold; T Deweese; R Rodriguez
Journal:  Cancer Gene Ther       Date:  2013-06-14       Impact factor: 5.987

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.